StockData
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp (ADPT) stock

ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30
$28.46−0.03 (-0.11%)

Close on Nov 18, 2026Market cap $4.54BP/E –Yield –

Adaptive Biotechnologies revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Adaptive Biotechnologies's revenue for the twelve months ending Jun 30, 2026 was $308.08M, up 50.1% year over year. For fiscal 2025 it was $276.98M, up 54.8% from the year before. The highest annual figure on record is $276.98M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$276.98M+54.8%
FY2024Dec 31, 2024$178.96M+5.1%
FY2023Dec 31, 2023$170.28M-8.1%
FY2022Dec 31, 2022$185.31M+20.1%
FY2021Dec 31, 2021$154.34M+56.9%
FY2020Dec 31, 2020$98.38M+15.6%
FY2019Dec 31, 2019$85.07M+52.8%
FY2018Dec 31, 2018$55.66M+44.8%
FY2017Dec 31, 2017$38.45M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$71.55M+21.5%
Q1 FY2026Mar 31, 2026$70.87M+35.1%
Q4 FY2025Dec 31, 2025$71.68M+51.0%
Q3 FY2025Sep 30, 2025$93.97M+102.4%
Q2 FY2025Jun 30, 2025$58.88M+36.3%
Q1 FY2025Mar 31, 2025$52.44M+25.2%
Q4 FY2024Dec 31, 2024$47.46M+3.7%
Q3 FY2024Sep 30, 2024$46.44M+22.5%
Q2 FY2024Jun 30, 2024$43.19M-11.7%
Q1 FY2024Mar 31, 2024$41.87M+11.2%
Q4 FY2023Dec 31, 2023$45.78M-17.1%
Q3 FY2023Sep 30, 2023$37.92M-20.7%
Q2 FY2023Jun 30, 2023$48.93M+12.1%
Q1 FY2023Mar 31, 2023$37.65M-2.5%
Q4 FY2022Dec 31, 2022$55.20M+45.5%
Q3 FY2022Sep 30, 2022$47.83M+21.2%
Q2 FY2022Jun 30, 2022$43.66M+13.4%
Q1 FY2022Mar 31, 2022$38.62M+0.5%
Q4 FY2021Dec 31, 2021$37.93M+25.7%
Q3 FY2021Sep 30, 2021$39.47M+50.1%
Q2 FY2021Jun 30, 2021$38.51M+83.5%
Q1 FY2021Mar 31, 2021$38.44M+83.8%
Q4 FY2020Dec 31, 2020$30.19M+24.7%
Q3 FY2020Sep 30, 2020$26.30M+0.9%
Q2 FY2020Jun 30, 2020$20.99M-5.2%
Q1 FY2020Mar 31, 2020$20.91M+65.1%
Q4 FY2019Dec 31, 2019$24.21M+40.8%
Q3 FY2019Sep 30, 2019$26.06M+51.6%
Q2 FY2019Jun 30, 2019$22.14M+91.4%
Q1 FY2019Mar 31, 2019$12.67M–
Q4 FY2018Dec 31, 2018$17.19M–
Q3 FY2018Sep 30, 2018$17.19M–
Q2 FY2018Jun 30, 2018$11.57M–

More Adaptive Biotechnologies figures

See a number that looks wrong?